625 related articles for article (PubMed ID: 22911364)
1. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma.
Chen YL; Uen YH; Li CF; Horng KC; Chen LR; Wu WR; Tseng HY; Huang HY; Wu LC; Shiue YL
Ann Surg Oncol; 2013 Nov; 20(12):4041-54. PubMed ID: 22911364
[TBL] [Abstract][Full Text] [Related]
2. Karyopherin α2-dependent import of E2F1 and TFDP1 maintains protumorigenic stathmin expression in liver cancer.
Drucker E; Holzer K; Pusch S; Winkler J; Calvisi DF; Eiteneuer E; Herpel E; Goeppert B; Roessler S; Ori A; Schirmacher P; Breuhahn K; Singer S
Cell Commun Signal; 2019 Nov; 17(1):159. PubMed ID: 31783876
[TBL] [Abstract][Full Text] [Related]
3. Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma.
Hsieh SY; Huang SF; Yu MC; Yeh TS; Chen TC; Lin YJ; Chang CJ; Sung CM; Lee YL; Hsu CY
Mol Carcinog; 2010 May; 49(5):476-87. PubMed ID: 20232364
[TBL] [Abstract][Full Text] [Related]
4. CKS1B overexpression implicates clinical aggressiveness of hepatocellular carcinomas but not p27(Kip1) protein turnover: an independent prognosticator with potential p27 (Kip1)-independent oncogenic attributes?
Huang CW; Lin CY; Huang HY; Liu HW; Chen YJ; Shih DF; Chen HY; Juan CC; Ker CG; Huang CY; Li CF; Shiue YL
Ann Surg Oncol; 2010 Mar; 17(3):907-22. PubMed ID: 19866239
[TBL] [Abstract][Full Text] [Related]
5. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
[TBL] [Abstract][Full Text] [Related]
6. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.
Chen HC; Jeng YM; Yuan RH; Hsu HC; Chen YL
Ann Surg Oncol; 2012 Jun; 19(6):2011-9. PubMed ID: 22146883
[TBL] [Abstract][Full Text] [Related]
7. SND1 affects proliferation of hepatocellular carcinoma cell line SMMC-7721 by regulating IGFBP3 expression.
Yin J; Ding J; Huang L; Tian X; Shi X; Zhi L; Song J; Zhang Y; Gao X; Yao Z; Jing X; Yang J
Anat Rec (Hoboken); 2013 Oct; 296(10):1568-75. PubMed ID: 23878061
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional regulation of the mouse PNRC2 promoter by the nuclear factor Y (NFY) and E2F1.
Zhou D; Masri S; Ye JJ; Chen S
Gene; 2005 Nov; 361():89-100. PubMed ID: 16181749
[TBL] [Abstract][Full Text] [Related]
9. C/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation.
Lu GD; Leung CH; Yan B; Tan CM; Low SY; Aung MO; Salto-Tellez M; Lim SG; Hooi SC
Gastroenterology; 2010 Aug; 139(2):632-43, 643.e1-4. PubMed ID: 20347819
[TBL] [Abstract][Full Text] [Related]
10. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA LINC00630 facilitates hepatocellular carcinoma progression through recruiting transcription factor E2F1 to up-regulate cyclin-dependent kinase 2 expression.
Kang J; Huang X; Dong W; Zhu X; Li M; Cui N
Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S257-S268. PubMed ID: 34420405
[TBL] [Abstract][Full Text] [Related]
12. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma.
Yuan RH; Jeng YM; Chen HL; Lai PL; Pan HW; Hsieh FJ; Lin CY; Lee PH; Hsu HC
J Pathol; 2006 Aug; 209(4):549-58. PubMed ID: 16739096
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/ E2F transcription factor 1-dependent apoptotic pathway.
Sun HX; Xu Y; Yang XR; Wang WM; Bai H; Shi RY; Nayar SK; Devbhandari RP; He YZ; Zhu QF; Sun YF; Hu B; Khan M; Anders RA; Fan J
Hepatology; 2013 Mar; 57(3):1088-97. PubMed ID: 23212661
[TBL] [Abstract][Full Text] [Related]
14. Aberrant methylation of the CADM1 promoter is associated with poor prognosis in hepatocellular carcinoma treated with liver transplantation.
Zhang W; Zhou L; Ding SM; Xie HY; Xu X; Wu J; Chen QX; Zhang F; Wei BJ; Eldin AT; Zheng SS
Oncol Rep; 2011 Apr; 25(4):1053-62. PubMed ID: 21271221
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor-containing fibulin-like extracellular matrix protein 1, EFEMP1, a novel tumor-suppressor gene detected in hepatocellular carcinoma using double combination array analysis.
Nomoto S; Kanda M; Okamura Y; Nishikawa Y; Qiyong L; Fujii T; Sugimoto H; Takeda S; Nakao A
Ann Surg Oncol; 2010 Mar; 17(3):923-32. PubMed ID: 19898900
[TBL] [Abstract][Full Text] [Related]
16. A promoter region of the midkine gene that is frequently expressed in human hepatocellular carcinoma can activate a suicide gene as effectively as the alpha-fetoprotein promoter.
Tomizawa M; Yu L; Wada A; Tamaoki T; Kadomatsu K; Muramatsu T; Matsubara S; Watanabe K; Ebara M; Saisho H; Sakiyama S; Tagawa M
Br J Cancer; 2003 Sep; 89(6):1086-90. PubMed ID: 12966430
[TBL] [Abstract][Full Text] [Related]
17. The TNF-α/ROS/HIF-1-induced upregulation of FoxMI expression promotes HCC proliferation and resistance to apoptosis.
Xia L; Mo P; Huang W; Zhang L; Wang Y; Zhu H; Tian D; Liu J; Chen Z; Zhang Y; Chen Z; Hu H; Fan D; Nie Y; Wu K
Carcinogenesis; 2012 Nov; 33(11):2250-9. PubMed ID: 22831955
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of WWP1 promotes tumorigenesis and predicts unfavorable prognosis in patients with hepatocellular carcinoma.
Zhang XF; Chao J; Pan QZ; Pan K; Weng DS; Wang QJ; Zhao JJ; He J; Liu Q; Jiang SS; Chen CL; Zhang HX; Xia JC
Oncotarget; 2015 Dec; 6(38):40920-33. PubMed ID: 26506518
[TBL] [Abstract][Full Text] [Related]
19. DNA methylation profiling identifies EYA4 gene as a prognostic molecular marker in hepatocellular carcinoma.
Hou X; Peng JX; Hao XY; Cai JP; Liang LJ; Zhai JM; Zhang KS; Lai JM; Yin XY
Ann Surg Oncol; 2014 Nov; 21(12):3891-9. PubMed ID: 24306662
[TBL] [Abstract][Full Text] [Related]
20. Stathmin 1 promotes the progression of liver cancer through interacting with YAP1.
Liu YP; Pan LL; Kong CC
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7335-7344. PubMed ID: 32706072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
